If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-14. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Braden Eric Peters (born 2005 or 2006), better known as Clavicular or Clav, is an American livestreamer, internet personality, and influencer. He rose to popularity on social media in 2025–2026 for promoting "looksmaxxing", a trend of using extreme methods to improve one's appearance, such as "bonesmashing", a pseudoscientific practice involving hitting one's facial bones with a hammer or fist, as well as the use of anabolic steroids and methamphetamine as an appetite suppressant. On September 8, 2026, charges were filed against Peters in Massachusetts state court for criminal rape, drugging, and providing alcohol to a minor.
Konstantin Kisin (Russian: Константин Вадимович Кисин; born 25 December 1982); Russian-British satirist, author, and co-host of Triggernometry podcast; has written for conservative Jewish Tablet (magazine), Quillette, right-libertarian Spiked (magazine), The Spectator, The Daily Telegraph and Standpoint; has been on the panel of the BBC political programme Question Time, and has appeared on BBC, Sky News and GB News. He speaks and writes on issues relating to tech censorship, comedy and culture war. He is the author of An Immigrant's Love Letter to the West, a 2022 non-fiction which became a Sunday Times bestseller in the first week of its publication. Jenny Kleeman; journalist, author, broadcaster; has reported for Channel 4's foreign affairs series Unreported World and BBC One's Panorama,; was presenter on Times Radio; She regularly writes for The Guardian and The Sunday Times Magazine. has reported for HBO's Vice News Tonight, Channel 4's Dispatches, The One Show on BBC One as well as making films for Unreported World; was nominated for Amnesty International Gaby Rado memorial award for her work.
To ensure the safety of blood components, regimented procedures and quality assurance systems must be in place covering all aspects of the transfusion chain, from donation to transfusion outcomes. Within hospitals, transfusion committees are established to ensure safe hospital transfusion practice such as compliance with standards and guidelines, reviewing transfusion reactions and management of blood supply. These multidisciplinary committees are composed of transfusion medicine specialists, transfusion nurses, laboratory scientists, clinicians and staff from hospital management and the quality team.
Sources: en.wikipedia.org
==== Mesocorticolimbic pathway ==== Understanding the pathways in which drugs act and how drugs can alter those pathways is key when examining the biological basis of drug addiction. The reward pathway, known as the mesolimbic pathway, or its extension, the mesocorticolimbic pathway, is characterized by the interaction of several areas of the brain. Dopaminergic neurons in the ventral tegmental area (VTA) fire in response to cues that predict a reward and project to the nucleus accumbens through the mesolimbic pathway; nearly all addictive drugs increase dopamine release along this pathway, although they act on it by different routes. The nucleus accumbens, made up largely of GABAergic medium spiny neurons, is a principal target of these projections and is involved in learning conditioned responses to drug-associated cues, and in the growing sensitivity to those cues as addiction progresses. A further target is the prefrontal cortex, including the anterior cingulate and orbitofrontal cortices, which weighs competing information in determining whether a behavior is carried out and forms the associations between drug reward and environmental cues that give those cues their power. These cues are strong mediators of drug-seeking behavior and can trigger relapse even after months or years of abstinence.
Mice resulting from ordinary breeding and inbreeding: Non-obese diabetic (NOD) mice, which develop diabetes mellitus type 1. Murphy Roths large (MRL) mice, with unusual regenerative capacities Japanese waltzing mice, which walk in a circular pattern due to a mutation adversely affecting their inner ears Immunodeficient nude mice, lacking hair and a thymus: these mice do not produce T lymphocytes; therefore, they do not mount cellular immune responses. They are used for research in immunology and transplantation. Severe combined immunodeficiency (SCID) mice, with an almost completely defective immune system FVB mice, whose large litter sizes and large oocyte pronuclei expedite use in genetic research Toxic milk mice, which fail to recruit nutrient copper into milk causing pup death. It is caused by an autosomal recessive mutation tx which arose in an inbred. Theophilos et al. 1996 found this to be genetic and localized to chromosome 8, near the centromere.
== Curtius rearrangement == The Bergmann degradation makes use of the azide degradation described by the Curtius rearrangement. Curtius also attempted to degrade benzoylated amino acids; however, his method involved splitting the carbamate with strongly energetic treatment with acids, which lead to decomposition of the resultant aldehyde and acid amides. This convinced Bergmann that Curtius' azide degradation could be followed by treatment with benzyl alcohol (his carbobenzoxy method) to isolate the resultant amino acid aldehyde and residual peptide amide for sequencing purposes.
== Other branches of anatomy == Surface anatomy is important as the study of anatomical landmarks that can be readily seen from the exterior contours of the body. It enables medics and veterinarians to gauge the position and anatomy of the associated deeper structures. Superficial is a directional term that indicates that structures are located relatively close to the surface of the body. Comparative anatomy relates to the comparison of anatomical structures (both gross and microscopic) in different animals. Artistic anatomy relates to anatomic studies of body proportions for artistic reasons.
Sources: en.wikipedia.org
=== Stability in aqueous solution === In aqueous solutions, bronopol is most stable when the pH of the system is on the acid side of neutral. Temperature also has a significant effect on stability in alkaline systems.
== Specimen processing == For blood tests, clinical chemists must process the specimen to obtain plasma and serum before testing for targeted analytes. This is most easily done by centrifugation, which packs the denser blood cells and platelets to the bottom of the centrifuge tube, leaving the liquid serum fraction resting above the packed cells. This initial step before analysis has recently been included in instruments that operate on the "integrated system" principle. Plasma is obtained by centrifugation before clotting occurs.
or the coupling reagent COMU which is readily soluble as a dimethylmorpholine-uronium salt and which, like Oxyma, is superior to the standard additive HOBt for the suppression of racemization and acylation efficiency and is comparable to HOAt without presenting an explosion risk such as the benzotriazoles. With water-soluble derivatives of ethyl cyanohydroxyiminoacetate (glyceroacetonide-oxyma) as additive and DIC as coupling reagent even in weakly basic aqueous solutions the linking of protected amino acids to oligopeptides is possible with a yield of 95% and a diastereomeric excess of> 99% using the model substances Z-L-Phg-OH and L-H-Pro-NH2.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.